Hidenobu Kondo

Dr. Hidenobu Kondo has been working in the Japanese CRO for about ten years. He has been consulting for Risk-based monitoring and been planning the RBM strategies for about 30 clinical trials of 10 companies in Japan since 2015. He studied pharmacy at Keio University in Japan. After his studies he spent six years at A2 Healthcare Corporation in CRA. In addition, he received his PhD from the Tohoku University Graduate School of Medicine in 2021. His research is focused on the RBM methods. He is also a part-time lecturer at Tohoku University starting in April 2022..